The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
An interesting development is that apparently an experimental drug, aimed to help people with Alzheimer’s, could play a role in helping children with certain types of Autims. Read the full story in our link for today.
Clinical trials of Alzheimer’s medicines have failed frequently but now researchers believe that this may have been caused by the drugs given too late. So if they could just develop a test that would detect Alzheimer’s earlier, it would make the drugs that have failed for use later in the process, so much more productive.
A laboratory study has found that the asthma drug salbutamol prevents the formation of tangles of fibrous protein that are a hallmark of Alzheimer’s disease. The next step will be to test the drug in animal models of the disease.
For this to hit the market: There are two drugs that have been developed by Salk Institute researchers to successfully treat Alzheimer’s in mice—and now, they have found that the very same drug compounds can also slow the aging process in the brains of healthy older mice.
Despite many promising leads, more than 120 drug treatments for Alzheimer’s disease have failed. But Cambridge-based biotech company Biogen revived hope on Tuesday with its announcement that it would seek Food and Drug Administration approval for a drug it abandoned earlier this year.
The biotech world went into a full-on frenzy Tuesday when drug giant Biogen dropped this whopper: The company is reviving its Alzheimer’s drug hopeful, aducanumab, after leaving it for dead all the way back in March. In fact, it’s marching forward with a Food and Drug Administration (FDA) application to approve the drug for certain patients facing cognitive decline.
An Alzheimer’s vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, a rare step forward in the fight against the brain-wasting disease, the company said on Monday.
The companies developing aducanumab, Biogen and its partner Eisai, announced that they halted two late-stage trials of the experimental drug after an independent group’s analysis showed that the trials were unlikely to “meet their primary endpoint.”
The Cambridge, Massachusetts-based biotech giant joins a long list of companies in the last decade that have failed to find a treatment for Alzheimer’s.
Check out the project in the link for today. The claim is a novel process to find a way to immunize against Alzheimer’s disease. Not sure how this low budget will win from all the billions already spent by the large pharmaceutical companies but see for yourself.
A new drug shows promising results: Early results indicate that the drug could reverse natural, age-related cognitive decline. Researchers also believe that it might help patients whose memories are impaired because of conditions such as depression, schizophrenia and Alzheimer’s disease.